Useful Supplement to the Best Practice of Using Levosimendan in Cardiac Surgery Patients: 2.5-mg Intravenous Bolus for Cardiopulmonary Resuscitation During Perioperative Cardiac Arrest

Carev, Mladen; Karanović, Nenad; Kocen, Dubravka; Bulat, Cristijan

doi:10.1053/j.jvca.2013.07.018

Cited by 5 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These beneficial effects may be explained not only by its dose-dependent positive inotropic action without increasing myocardial oxygen uptake (rather, elevating oxygen availability), but also by amelioration of myocardial mitochondrial dysfunction (7,9,10). In addition, several clinical cases have implied that levosimendan is often applied as a ''last resort'' therapy for patients after failure of standard treatment in refractory CA (14,15). However, only few previous studies have aimed to explore its potential application in improving microcirculatory blood flow, vascular reactivity, and intestinal mucosal and microvascular oxygenation during experimental septic shock (16,17).…”

Section: Introductionmentioning

confidence: 99%

Levosimendan Ameliorates Post-resuscitation Acute Intestinal Microcirculation Dysfunction Partly Independent of its Effects on Systemic Circulation: A Pilot Study on Cardiac Arrest in a Rat Model

Jia

Wang

Luo

et al. 2021

Shock

View full text Add to dashboard Cite

Background: Cardiac arrest (CA) is recognized as a life-threatening disease; however, the initial resuscitation success rate has increased due to advances in clinical treatment. Levosimendan has shown potential benefits in CA patients. However, its exact function on intestinal and systemic circulation in CA or post-cardiac arrest syndrome (PCAS) remained unclear. This study preliminarily investigated the link between dynamic changes in intestine and systemic hemodynamics post-resuscitation after levosimendan administration. Methods: Twenty-five rats were randomized into three groups: sham control group (n ¼ 5), levosimendan group (n ¼ 10), and vehicle group (n ¼ 10). Intestinal microcirculation was observed using a sidestream dark-field imaging device at baseline and each hour of the return of spontaneous circulation ( 6 h). Systemic hemodynamics, serum indicators of cardiac injury, and tissue perfusion/metabolism were measured by echo-cardiography, a biological signal acquisition system, and an enzyme-linked immunosorbent assay, respectively. Results: Myocardial injury and global and intestinal perfusion/metabolism were significantly improved by levosimendan treatment. There was no statistically significant difference in the mean arterial pressure values between the vehicle and levosimendan groups (P > 0.05). The intestinal and systemic circulation measurements showed poor correlation (Pearson r-value of variable combinations in the levosimendan group was much less than 0.75; P < 0.01, levosimendan vs. vehicle group). Conclusions: Levosimendan significantly reduced the cardiac injury and corrected the metabolic status in an experimental rat model of ventricular fibrillation induced CA and cardiopulmonary resuscitation. Levosimendan may ameliorate PCAS-induced intestinal microcirculation dysfunction, partly independent of its effects on macrocirculation.

show abstract